Last reviewed · How we verify
Diltiazem intravenous
At a glance
| Generic name | Diltiazem intravenous |
|---|---|
| Sponsor | Haseki Training and Research Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Adenosine vs. Diltiazem (PHASE4)
- Catheter Ablation Versus Anti-arrhythmic Drugs for Premature Ventricular Complexes (NA)
- Oral Bisoprolol Vs IV Diltiazem in Atrial Fibrillation or Flutter With Rapid Ventricular Rate. (PHASE3)
- Effect of Oral and Intravenous Diltiazem Protocol for Emergency Department Atrial Fibrillation (PHASE4)
- Prognostic Value of Precision Medicine in Patients With MINOCA (PROMISE Trial). (PHASE4)
- Rhythm Control Versus Rate Control for New Onset Atrial Fibrillation (NA)
- Oral vs Intravenous Diltiazem for Rapid Atrial Fibrillation/Flutter Trial (PHASE4)
- Pre-diltiazem, Calcium Versus Placebo for Atrial Fibrillation With Rapid Ventricular Response (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Diltiazem intravenous CI brief — competitive landscape report
- Diltiazem intravenous updates RSS · CI watch RSS
- Haseki Training and Research Hospital portfolio CI